Novartis' Fabhalta Demonstrates Significant Proteinuria Reduction In IgA Nephropathy Patients
16/4 05:28
(RTTNews) - Novartis (NVS) presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy or IgAN. Results were pre...